Entering text into the input field will update the search result below

Sell-siders cut views on Tivity Health after ugly Q4

  • Hutchison China MediTech (NASDAQ:HCM) initiated with Buy rating and $38 (38% upside) price target at Goldman Sachs.
  • Eidos Therapeutics (NASDAQ:EIDX) initiated with Buy rating and $66 (27% upside) price target at Guggenheim.
  • Intra-Cellular Therapies (NASDAQ:ITCI) initiated with Outperform rating at Evercore ISI.
  • Community Health Systems (NYSE:CYH) upgraded to Market Perform at Raymond James after Q4 report.
  • Galapagos NV (NASDAQ:GLPG) downgraded to Underperform with a $175 (34% downside risk) price target at RBC.
  • PTC Therapeutics (NASDAQ:PTCT) downgraded to Sector Perform with a $60 (1% upside) price target at RBC.
  • Tivity Health (NASDAQ:TVTY) downgraded to Hold with a $16 (30% downside risk) price target at Jefferies. Downgraded to Hold with a $15 price target at SunTrust. Downgraded to Market Perform at William Blair. Downgraded to Neutral with a $17 price target at Cantor Fitzgerald, all after its ugly Q4.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
HCM--
HUTCHMED (China) Limited
EIDX--
Eidos Therapeutics, Inc.
ITCI--
Intra-Cellular Therapies, Inc.
CYH--
Community Health Systems, Inc.
GLPG--
Galapagos NV